Related Blog Posts from the Wikinvest Wire

Abbott Laboratories (ABT)   Subscribe to Abbott Laboratories (ABT) content from the Wikinvest Wire
 » Back to Abbott Laborato… (NYSE:ABT) Stock Page

  

11/13/14Market Update (NYSE:ABBV): AbbVie’s Leadership in Immunology Featured at 2014 American College ... (Jutia Group)

[PR Newswire] - NORTH CHICAGO, Ill., Nov. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA ® (adalimumab), rheumatologic diseases and investigational medicines will ... Read more on this. AbbVie Inc. (ABBV), valued at $101.34B, opened this morning at $64.21.   Looking at [...]

10/29/14Stock Update: Abbott Laboratories (NYSE:ABT) – Abbott Expands Its Medical Device Business with ... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Oct. 29, 2014 /PRNewswire/ -- Abbott (ABT) today announced that it has entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation, one of the most common heart rhythm [...]

10/22/14Company Update (NYSE:ABT): Abbott Reports Third-Quarter 2014 Results (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Oct. 22, 2014 /PRNewswire/ -- Abbott today announced financial results for the third quarter ended Sept. 30, 2014. Diluted EPS, excluding specified items, was $0.62 in the third quarter, ... Read more on this. Abbott Laboratories (ABT), currently valued at $63.41B, began trading this morning at $42.42. [...]

9/26/14Company Update: Abbott Laboratories (NYSE:ABT) – Abbott Completes Acquisition of CFR Pharmaceut... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Sept. 26, 2014 /PRNewswire/ -- Abbott (ABT) has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets. Through purchase of the controlling interest and tender offers described below, Abbott indirectly acquired more than [...]

9/25/14Company Update (NYSE:ABBV): AbbVie’s HUMIRA® (adalimumab) Receives U.S. FDA Approval for the T... (Jutia Group)

[PR Newswire] - NORTH CHICAGO, Ill., Sept. 25, 2014 /PRNewswire/ -- AbbVie (ABBV) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have [...]

9/15/14Stock Update: Abbott Laboratories (NYSE:ABT) – Abbott Initiates ABSORB IV Trial to Evaluate Qua... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Sept. 15, 2014 /PRNewswire/ -- Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. ABSORB IV is designed [...]

9/11/14Company Update: Abbott Laboratories (NYSE:ABT) – Abbott Announces New $3 Billion Share Repurcha... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Sept. 11, 2014 /PRNewswire/ -- Abbott's (ABT) board of directors has approved a new share repurchase program and declared a quarterly common dividend. This marks the 363rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2014, to shareholders of [...]

9/11/14Stock Update (NYSE:ABBV): AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (... (Jutia Group)

[PR Newswire] - COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA ® (adalimumab) is effective in reducing common clinical ... Read more on this. AbbVie Inc. (ABBV), with a current value of $91.22B, began trading this morning at $56.98. [...]

9/8/14Market Update (NYSE:ABBV): AbbVie, Teva broke law in AndroGel "pay for delay" deal, U.S. says (Jutia Group)

[Reuters] - The U.S. Federal Trade Commission on Monday sued Drugmakers AbbVie Inc and Teva Pharmaceuticals Industries Ltd for allegedly illegally preventing generic versions of AndroGel, for men with low testosterone, ... Read more on this. AbbVie Inc. (ABBV), with a current value of $88.45B, started the session at $55.78.   [...]

9/8/14Stock Update: Abbott Laboratories (NYSE:ABT) – New Abbott Technology May Uncover the Root of Cr... (Jutia Group)

[PR Newswire] - WASHINGTON, Sept. 8, 2014 /PRNewswire/ -- A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (€1.5 million / £1.2 million).[1] The cost reductions are based on a health [...]

9/3/14Stock Update: Abbott Laboratories (NYSE:ABT) – Abbott Receives CE Mark for FreeStyle® Libre, a... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes. The system eliminates the need for routine finger pricks1, reading glucose levels through [...]

8/25/14Market Update: Abbott Laboratories (NYSE:ABT) – Abbott Commences Tender Offer for All Outstandi... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Aug. 25, 2014 /PRNewswire/ -- Abbott (ABT) today announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer (the "U.S. Offer"), in which it is offering to purchase (i) from U.S. Read more on this. Abbott Laboratories [...]

8/12/14Market Update (NYSE:ABT): Access to Abbott’s MitraClip® System Expands in the U.S. with Medica... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Aug. 12, 2014 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) recently issued a National Coverage Determination (NCD) that extends coverage for Medicare beneficiaries ... Read more on this. Abbott Laboratories (ABT), currently valued at $62.45B, opened this morning at $41.91.   [...]

7/28/14Market Update (NYSE:ABT): Abbott to Showcase Innovations to Help Labs Solve Health Care Challenge... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., July 28, 2014 /PRNewswire/ -- Clinical laboratories around the world are helping to improve patient care while navigating an evolving health care environment. To help laboratories with increasing demands, Abbott (ABT) is developing diagnostic solutions for today and tomorrow, which it will showcase during the American Association for [...]

7/24/14Market Update: Abbott Laboratories (NYSE:ABT) – Abbott Introduces New Similac® Breastfeeding S... (Jutia Group)

[PR Newswire] - Abbott (ABT), the makers of Similac® and experts in infant nutrition for nearly 90 years, studied the diets of more than 80 lactating women to assess how their nutritional intake compared to dietary recommendations. The research found few lactating women consistently consume enough key nutrients, like DHA, lutein and vitamin E, [...]

7/14/14Market Update: Abbott Laboratories (NYSE:ABT) – Mylan To Acquire Abbott’s Non-U.S. Developed ... (Jutia Group)

[PR Newswire] - PITTSBURGH, July 14, 2014 /PRNewswire/ -- Mylan Inc. (MYL) today announced that it has entered into a definitive agreement with Abbott (ABT) whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business ("the Assets") in an all-stock transaction. Upon closing, Abbott will receive 105 million shares of the [...]

5/16/14Abbott Laboratories (NYSE:ABT) | Abbott Expands Latin American Presence and Branded Generics Port... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., May 16, 2014 /PRNewswire/ -- Abbott (ABT) today announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding Abbott's presence in fast-growing markets. Under the terms of the agreement, Abbott will acquire the [...]

5/12/14Company Update: Abbott Laboratories (NYSE:ABT) – Promising Preliminary Data Show Abbott’s Inn... (Jutia Group)

[PR Newswire] - BARCELONA, Spain, May 12, 2014 /PRNewswire/ -- Abbott (ABT) today announced initial results that suggest its innovative testing platform, known as IRIDICA (currently in development), produces results consistent with the current standard of care in just hours. Currently, the diagnosis of serious infections, such as sepsis or pneumonia, can often take [...]

5/8/14Stock Update: Abbott Laboratories (NYSE:ABT) – Abbott Facility Receives Top International Award... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., May 8, 2014 /PRNewswire/ -- Abbott (ABT) has been awarded the Shingo Prize, an international award for operational excellence, by the Shingo Institute at the Jon M. Huntsman School of Business at Utah State University. Abbott's vascular devices manufacturing facility in Clonmel, Ireland, received the award, recognizing the [...]

5/1/14Abbott Laboratories (NYSE:ABT) – Abbott to Present at Deutsche Bank 39th Annual Health Care Con... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., May 1, 2014 /PRNewswire/ -- Abbott (ABT) will participate in the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014. Thomas C. Freyman, executive vice president, finance and chief financial officer will participate in a question and answer session regarding the company beginning at 8:20 [...]

3/28/14Abbott Laboratories (NYSE:ABT) – Abbott Announces FDA Approval of Its Supera® Stent to Treat P... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., March 28, 2014 /PRNewswire/ -- Abbott today announced that its Supera® Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). PAD occurs when fat and cholesterol buildup causes [...]

2/5/14Abbott Laboratories (NYSE:ABT) | Abbott Labs Sued by Five Men Claiming Androgel Injuries (Jutia Group)

[at Bloomberg] - Abbott Laboratories (ABT) and AbbVie Inc., the company it spun off last year, hid the dangers of using the testosterone replacement drug AndroGel, five men claimed in lawsuits. Their complaints, filed ... Read more on this. Abbott Laboratories (ABT), with a current market cap of $56.31B, started trading this morning [...]

1/30/14Company Update: Abbott Laboratories (NYSE:ABT) – Abbott to close Puerto Rico manufacturing plant (Jutia Group)

[AP] - Abbott Laboratories is closing one of its manufacturing plants in the Puerto Rico town of Barceloneta next year, delivering another blow to the U.S. territory's once-thriving pharmaceutical sector, officials ... Read more on this. Abbott Laboratories (ABT), with a current value of $56.48B, started the session at $36.20.   [...]

1/24/14Abbott Laboratories (NYSE:ABT) – Abbott’s Earnings Increase 22% Year Over Year, But Is It A Buy? (Jutia Group)

[at Seeking Alpha] - Abbott Laboratories ( ABT ) is engaged in the discovery, development, manufacture and sale of a portfolio of science-based healthcare products, which operates in four segments: Diagnostics, Medical Devices, ... Read more on this. Abbott Laboratories (ABT), valued at $56.54B, opened at $37.20.   Looking at [...]

1/22/14Abbott Laboratories (NYSE:ABT) | Abbott Reports Fourth-Quarter and Full-Year 2013 Results (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Jan. 22, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2013. Ongoing diluted EPS was $0.58 in the fourth quarter and ... Read more on this. Abbott Laboratories (ABT), currently valued at $58.88B, ended session yesterday at $39.12. [...]

1/21/14Company Update: Abbott Laboratories (NYSE:ABT) – GSK gets new trial against Abbott over gay jur... (Jutia Group)

[Reuters] - GlaxoSmithKline Plc deserves a new trial against Abbott Laboratories because Abbott impermissibly excluded a potential juror based on his sexual orientation, a federal appeals court ruled on Tuesday. GSK ... Read more on this. Abbott Laboratories (ABT), currently valued at $60.56B, started trading this morning at $39.53.   [...]

1/8/14Abbott Laboratories (NYSE:ABT) – 125 Years Of Healthcare Innovation and Still Growing (Jutia Group)

[at Motley Fool] - Now that the dust surrounding Abbott Laboratories has settled from the AbbVie spinoff, it’s much easier to get a clear picture of the company’s growth opportunities. Here are some factors to look out for ... Read more on this. Abbott Laboratories (ABT), with a current market cap of $60.44B, [...]

1/7/14Company Update – Abbott Laboratories (NYSE:ABT) – Will Abbott Perform Better In 2014? (Jutia Group)

[at Seeking Alpha] - By the end of the third quarter of 2013 Abbott Laboratories ( ABT ) increased its dividend payout for the 41st consecutive year. This marks the 359th consecutive quarterly dividend to be paid out by Abbott ... Read more on this. Abbott Laboratories (ABT), currently valued at $60.07B, started [...]

1/6/14Company Update – Abbott Laboratories (NYSE:ABT) – Abbott Hosts Conference Call for Fourth-Qua... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Jan. 6, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2013 financial results on Wednesday, Jan. 22, 2014, before the market opens. The announcement ... Read more on this. Abbott Laboratories (ABT), with a current market cap of $60.63B, began trading this morning [...]

12/17/13Stock Update: Abbott Laboratories (NYSE:ABT) – A Space Age View into Human Vision: Abbott’s i... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Dec. 17, 2013 /PRNewswire/ -- With the introduction of Abbott's iDesign Dx system, U.S. ophthalmologists now have a diagnostic tool that can capture five optical measurements in one three-second scan to determine the patient's visual abnormalities. Obtaining these measurements in one three-second scan enables ophthalmologists to screen patients [...]

12/12/13Abbott Laboratories (NYSE:ABT) | ModernGraham Valuation Of Abbott Laboratories (Jutia Group)

[at Seeking Alpha] - Here is a look at how Abbott Laboratories ( ABT ) fares in ModernGraham's opinion, based on an updated and modernized version of Benjamin Graham's requirements of defensive and enterprising investors from ... Read more on this. Abbott Laboratories (ABT), with a current market cap of $56.34B, started trading [...]

12/11/13Company Update – Abbott Laboratories (NYSE:ABT) – Abbott Laboratories Raised Its Dividend 57%... (Jutia Group)

[at Seeking Alpha] - The last time I wrote about Abbott Laboratories ( ABT ) I did not buy any more shares stating that I thought the stock had moved up too far up too quickly. The stock is down 2.65% since last writing the ... Read more on this. Abbott Laboratories (ABT), [...]

11/26/13Company Update – Abbott Laboratories (NYSE:ABT) – Will Google soon pass Exxon in market value? (Jutia Group)

[at CNNMoney.com] - The opinions expressed in this commentary are solely those of Paul R. La Monica. Other than Time Warner, the parent of CNNMoney, Abbott Laboratories and AbbVie, La Monica does not own positions in any ... Read more on this. Abbott Laboratories (ABT), currently valued at $58.99B, started trading this morning [...]

11/21/13AbbVie Inc. (NYSE:ABBV) ~ New Research And Competition Could Hurt AbbVie’s Other Blockbuster (Jutia Group)

[at Seeking Alpha] - Investors of AbbVie ( ABBV ) know that its stock price is mostly driven by the success of Humira, the best selling medication in the world. However AbbVie's second best selling medication is a testosterone ... Read more on this. AbbVie Inc. (ABBV), with a current value of $76.97B, [...]

11/18/13Stock Update: Abbott Laboratories (NYSE:ABT) – 1 Biotech Buy-and-Hold Lesson Wall Street Wants ... (Jutia Group)

[at Motley Fool] - Wall Street panicked at the end of 2000 when Abbott Labs announced it was acquiring the pharmaceutical business of BASF. Shares sank 7.1% the next trading day on fears of dilution and a lack of execution. ... Read more on this. Abbott Laboratories (ABT), currently valued at $58.69B, began [...]

11/14/13Company Update: Abbott Laboratories (NYSE:ABT) – Experience ″A Day in the Life″ of an Insul... (Jutia Group)

[PR Newswire] - ABBOTT PARK, Ill., Nov. 14, 2013 /PRNewswire/ -- In honor of World Diabetes Day, Abbott has created an interactive infographic to help raise awareness about what life can be like for an insulin-using patient who has diabetes. Many people with diabetes are prescribed insulin, either because their bodies do not produce [...]

11/4/13Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Vs. Abbvie In Potent... (Jutia Group)

[at Seeking Alpha] - Bristol-Myers Squibb ( BMY )'s new experimental drug for rheumatoid arthritis (RA) caused excitement at a conference in October. It appears that the drug clazakizumab is as effective as AbbVie ( ABBV )'s ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.31B, started trading this [...]

11/4/13AbbVie Inc. (NYSE:ABBV) | Bristol-Myers Vs. Abbvie In Potential Humira Rivalry (Jutia Group)

[at Seeking Alpha] - Bristol-Myers Squibb ( BMY )'s new experimental drug for rheumatoid arthritis (RA) caused excitement at a conference in October. It appears that the drug clazakizumab is as effective as AbbVie ( ABBV )'s ... Read more on this. AbbVie Inc. (ABBV), valued at $76.78B, opened this morning at $49.19. [...]

11/4/13Abbott Laboratories (NYSE:ABT) – Abbott Labs Lacks Diversification (Jutia Group)

[at TheStreet] - Given that shares of Abbott Labs It's true that Abbott's lack of revenue growth didn't give me that "warm and fuzzy" feeling about its competitive position against the likes of Roche "I believe the only way to justify buying this stock -- even on this recent pullback -- is for management [...]

10/29/13Abbott Laboratories (NYSE:ABT) – Who’s cutting the cord? Cable stocks soaring (Jutia Group)

[at CNNMoney.com] - The opinions expressed in this commentary are solely those of Paul R. La Monica. Other than Time Warner, the parent of CNNMoney, Abbott Laboratories and AbbVie, La Monica does not own positions in any ... Read more on this. Abbott Laboratories (ABT), valued at $58.08B, opened this morning at $37.30. During [...]

10/25/13Abbott Laboratories (NYSE:ABT) – AbbVie Profit Beats Estimates as Sales of Humira Increase (Jutia Group)

[at Bloomberg] - AbbVie Inc., the drugmaker that split from Abbott Laboratories in January, reported third- quarter earnings that beat analysts’ estimates as sales of its top drug Humira rose. The company raised the bottom ... Read more on this. Abbott Laboratories (ABT), currently valued at $57.88B, started trading this morning at $37.24. Shares [...]

8/21/13(ABT) Abbott Laboratories Announces CE Mark for Xpedition 48 Stent System (Stock Blog Hub)

Abbott Laboratories (ABT) recently announced that it received CE Mark in Europe for its drug eluting stent – Xience Xpedition 48 Everolimus Eluting Coronary Stent System. Xience Xpedition 48 is the latest addition to Abbott Labs’ Xience drug-eluting stent franchise. The product is designed to enable treatment for very long blockages in the vessels that supply blood [...]

5/2/13(ABT) Abbott Laboratories Launches Automated Solution (Stock Blog Hub)

Abbott Laboratories (ABT) recently announced that the company has launched ACCELERATOR a3600 – its next-generation track system to increase efficiency in laboratories. A laboratory automation track system, ACCELERATOR a3600 enables processing for up to 3,600 samples per hour along with handling multiple tube sizes and types simultaneously. Moreover, this system automates routine, manual tasks which in turn [...]

2/18/13(ABT) AbbVie Provides 2013 Outlook (Stock Blog Hub)

AbbVie (ABBV) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott Laboratories (ABT). AbbVie said that excluding the negative impact of currency fluctuation (3%), pharmaceutical segment revenues grew more than 8% in the fourth quarter of 2012 [...]

2/1/13Should dividend investors hold on to Abbott (ABT) and Abbvie (ABBV) following the split? (Dividend Growth Investor)

I have been a shareholder of Abbott Laboratories for several years. I liked the fact that the company was constantly undervalued, and also managed to offer a very attractive yield plus an above average dividend growth. My last addition to my position occurred in the final weeks of 2012. In my last analysis of the stock, I was bullish on its business going forward. On January 1, 2013, Abbott Laboratories split into two companies, one which retained its name Abbott Laboratories (ABT), and...

1/25/13Reconsidering Abbott Labs (ABT) And AbbVie (ABBV) (The DIV-Net)

Abbott Laboratories: A company I loved  At the beginning of this year, Abbott Laboratories (ABT) completed the spin-off of its branded pharmaceutical business. This business is now a separate publicly traded company, calling itself AbbVie Inc. (ABBV). I have long been a fan of Abbott Laboratories as a diversified health care company with operations in medical devices, diagnostics, branded pharmaceuticals and nutrition among other businesses. It's been in business since 1888 and it's been...

1/24/13Abbott Dividend Stock Analysis (The DIV-Net)

I have been a shareholder of Abbott Laboratories for several years. I liked the fact that the company was constantly undervalued, and also managed to offer a very attractive yield plus an above average dividend growth. My last addition to my position occurred in the final weeks of 2012. In my last analysis of the stock, I was bullish on its business going forward. On January 1, 2013, Abbott Laboratories split into two companies, one which retained its name Abbott Laboratories...

1/15/13(ABT) Abbott Laboratories’ ABSORB in Phase III Trial (Stock Blog Hub)

Abbott Laboratories (ABT) recently announced that its Absorb Bioresorbable Vascular Scaffold (BVS) device has moved into a phase III study, ABSORB III, in the US. The randomized, controlled study will enroll 2,250 patients and will compare Absorb BVS’s performance to the company's Xience drug eluting stents. We note that Absorb is available in Europe and some [...]

1/3/13Abbot Labs Jumps On FDA Approval For Heart Stent (Stock Wizard)

Shares of Abbott Laboratories (NYSE: ABT) surged as much as 3% on Thursday after the company announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received U.S. Food and Drug... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

12/21/12Abbott Laboratories: Quality Dividend Aristocrat for Long Term Dividends (Dividend Growth Investor)

Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. This dividend champion has boosted distributions for 40 years in a row. The company’s last dividend increase was in February 2012 when the Board of Directors approved a 6.30% increase to 51 cents/share. The company’s peer group includes Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY) and Merck (MRK). Over the past decade this dividend growth stock has...


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki